EQT Life Sciences leads USD 75 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington's disease

EQT Sweden

Atalanta Therapeutics is pioneering RNA interference (RNAi) for the treatment of neurological diseases, having developed a proprietary platform that, for the first time enables RNAi to be deployed as a therapeutic approach throughout the brain and spinal cordThe USD 75 million Series B financing will support Phase 1 clinical trials of the company's investigational RNAi therapies for KCNT1-related epilepsy and Huntington's diseaseEQT Life Sciences is leading the round investing from its LSP Dementia Fund, which is co-led by Sanofi Ventures with further participation from RiverVest Venture Partners, abrdn, Inc., Mirae Asset Financial Group and F-Prime CapitalView original content:https://www.prnewswire.co.uk/news-releases/eqt-life-sciences-leads-usd-75-million-series-b-in-atalanta-therapeutics-a-biotech-firm-developing-treatments-for-epilepsy-and-huntingtons-disease-302361914.html